Results 211 to 220 of about 10,846,594 (333)

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Francesca Caputo, Marta Simone, Massimiliano Copetti, Damiano Paolicelli, Emilio Portaccio, Francesco Patti, Paola Perini, Vincenzo Brescia Morra, Alessia Di Sapio, Matilde Inglese, Carlo Pozzilli, Giacomo Lus, Giuseppe Salemi, Erica Curti, Giovanna De Luca, Paola Valentino, Eleonora Cocco, Paola Cavalla, Carlo Avolio, Alessandra Lugaresi, Antonio Gallo, Pietro Annovazzi, Maria A. Rocca, Clara Grazia Chisari, Massimo Filippi, Maria Pia Amato, Maria Trojano, on behalf of the Italian MS Register, Beatrice Biolzi, Daniele Dell’Anna, Daniele Di Giulio Cesare, Sonia Di Lemme, Chiara Di Tillio, Teresa Fonsdituri, Ilaria Maietta, Agata Marchese, Silvia Marinetto, Federica Martini, Cristiana Morano, Silvia Perugini, Giovanna Ramona Piredda, Chiara Raimondi, Ilaria Rossi, Valentina Tallarico, Stefania Treccarichi   +47 more
wiley   +1 more source

What to do when the unwanted happens? Negative event management in studies on internet- and mobile-based interventions for youths and adults with two case reports. [PDF]

Internet Interv
Schulte C, Sextl-Plötz T, Baumeister H, Titzler I, Sander LB, Sachser C, Steubl L, Zarski AC.   +7 more
europepmc   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski, Aurélie Ledreux, John E. Violette, Whitney Paustian, Stefan Sillau, John A. Thompson, Robert T. Neumann, David Ornelas, Andrew A. Monte, Layne Dylla, Adit A. Ginde, Andra M. Farcas, Christina M. Coughlan, William J. Jones, James C. Grotta, Michael W. Graner   +15 more
wiley   +1 more source

Distributed Event Detection in Wireless Sensor Networks for Disaster Management [PDF]

, 2010
Majid Bahrepour, Nirvana Meratnia, Mannes Poel, Zahra Taghikhaki, Paul Havinga   +4 more
openalex   +1 more source

The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To quantify how often anti‐seizure medications (ASMs) appear ineffective yet provide benefit when considering seizure frequency (SF) variability. Methods We used the CHOCOLATES seizure diary simulator to generate 100,000 patient seizure diaries that reflect natural SF variation in a heterogeneous population.
Christopher N. Henry, Daniel M. Goldenholz   +1 more
wiley   +1 more source

Quality assurance and adverse event management in regenerative medicine for knee osteoarthritis: Current concepts. [PDF]

J Clin Orthop Trauma, 2019
Marenah M, Li J, Kumar A, Murrell W.
europepmc   +1 more source

Quantitative Shape Irregularity and Density Heterogeneity Predict Hematoma Expansion in Patients With Intracerebral Hemorrhage

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose This study aimed to explore the association between quantitative shape irregularity and density heterogeneity of hematomas and hematoma expansion (HE) for intracerebral hemorrhage (ICH) patients. Methods This cohort study included patients arriving within 24 h of symptom onset between August 2021 and July 2022 as the derivation cohort ...
Zeqiang Ji, Yunyi Hao, Bin Gao, Xiaojing Zhang, Yani Zhang, Jiaokun Jia, Xue Xia, Yuhao Guo, Sijia Li, Jianwei Wu, Kaijiang Kang, Xingquan Zhao   +11 more
wiley   +1 more source

Comparison of clozapine monitoring and adverse event management in a psychiatrist-only and a clinical pharmacist-psychiatrist collaborative clinic. [PDF]

Ment Health Clin, 2019
Maryan S, Harms M, McAllister E, DeJongh B.   +3 more
europepmc   +1 more source

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis. Methods Clinical information was collected prospectively on Research Electronic Data Capture.
Nabil K. El Ayoubi, Fares Fahd, Hani Tamim, Salem Hannoun, Mark Bal, Elham El‐Hallak, Samia J. Khoury   +6 more
wiley   +1 more source